MKC 1

Drug Profile

MKC 1

Alternative Names: MKC-1; R 440; RO 31-7453

Latest Information Update: 18 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer CASI Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Hypoxia-inducible factor-1 alpha inhibitors; Importin beta protein inhibitors; Mitosis inhibitors; MTOR protein inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Breast cancer; Haematological malignancies; Leukaemia; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 16 Jun 2014 EntreMed is now called CASI Pharmaceuticals
  • 10 Nov 2008 MKC 1 meets primary efficacy endpoint in open-label phase I/II study in non-small cell lung cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top